羊水栓塞相关消耗性凝血病:重症监护中早期评估以指导干预的重要性
本研究为单中心回顾性病例对照研究,比较符合Clark标准的羊水栓塞患者(Clark组,n=6)、符合日本标准但不符合Clark标准者(Non-Clark组,n=10)与围产期对照的早期凝血病指标。结果发现Clark组全部患者及Non-Clark组多数患者的纤维蛋白原水平较血红蛋白更早下降,与高血红蛋白/纤维蛋白原比值一致,提示该比值是早期评估羊水栓塞相关消耗性凝血病的有前景临床标志物。作者认为,在预防性治疗基础上通过该比值早期评估消耗性凝血病及纤溶亢进,可能减少或预防严重凝血病的发生或加重。
要点
- Clark组全部患者及Non-Clark组多数患者的纤维蛋白原水平较血红蛋白更早下降,支持高血红蛋白/纤维蛋白原比值作为早期评估指标。
- 符合日本标准但不符合Clark标准的羊水栓塞患者中可能存在以消耗性凝血病为先导的病例,是早期评估和干预的潜在临床目标。
- 研究纳入Clark组6例、Non-Clark组10例及围产期对照,比较输血前纤溶参数等指标。
- 作者提出,基于血红蛋白/纤维蛋白原比值早期评估消耗性凝血病及纤溶亢进,并配合预防性治疗,可能减少或预防严重凝血病的发生或加重。
适用人群与场景
- 羊水栓塞患者,分为符合Clark标准者(Clark组,n=6)和符合日本标准但不符合Clark标准者(Non-Clark组,n=10),并设围产期对照。
- 研究场景为单中心大学附属医院,基于2003年以来的羊水栓塞登记项目,纳入2009至2017年病例。
诊断标准与关键阈值
- Clark标准:严重凝血病合并心肺功能不全。
- 日本标准:临床实践中还包括产后出血或弥散性血管内凝血。
- 原文未提及具体的评分界值或启动/停止阈值。
处置流程与药物剂量
- 原文未提及具体的处置流程或药物剂量方案。
- 作者提出,在预防性治疗基础上,通过血红蛋白/纤维蛋白原比值早期评估消耗性凝血病及纤溶亢进,可能减少或预防严重凝血病的发生或加重。
红旗征与不能漏的情况
- 原文未提及具体的红旗征或不能漏诊的情况。
研究设计与关键结果
- 研究类型为回顾性病例对照研究,单中心,样本为Clark组6例、Non-Clark组10例及围产期对照。
- Clark组全部患者及Non-Clark组多数患者的纤维蛋白原水平较血红蛋白水平更早下降,与高血红蛋白/纤维蛋白原比值一致。
证据类型、等级与局限
- 证据类型为回顾性病例对照研究。
- 原文未述局限性。
对床旁实践的改变
- 在羊水栓塞患者中,尤其是符合日本标准但不符合Clark标准者,可考虑早期评估消耗性凝血病。
- 血红蛋白/纤维蛋白原比值是早期评估羊水栓塞相关消耗性凝血病的有前景临床标志物,但原文未给出具体阈值。
- 作者提出,基于该比值早期评估并配合预防性治疗,可能减少或预防严重凝血病的发生或加重。
- 原文未提及适用与不适用人群的具体区分或常见陷阱。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Amniotic fluid embolism is a rare disease that induces fatal coagulopathy; however, due to its rarity, it has not yet been examined in detail. The strict diagnostic criteria by Clark for amniotic fluid embolism include severe coagulopathy complicated by cardiopulmonary insufficiency, whereas the Japanese criteria also include postpartum hemorrhage or Disseminated Intravascular Coagulation in clinical practice. Amniotic fluid embolism cases with preceding consumptive coagulopathy may exist and are potential clinical targets for earlier assessments and interventions among amniotic fluid embolism cases fulfilling the Japanese, but not Clark criteria. The present study was performed to compare coagulopathy in the earlier stage between the amniotic fluid embolism patients diagnosed by Clark criteria (Clark group, n = 6), those by the Japanese criteria (Non-Clark group, n = 10), and peripartum controls and identify optimal clinical markers for earlier assessments of amniotic fluid embolism-related consumptive coagulopathy.
DESIGN: Retrospective case-control study.
SETTING: A single university-based center. Our amniotic fluid embolism registry program has accumulated clinical information and blood samples since 2003.
PATIENTS: Amniotic fluid embolism patients in the Clark and Non-Clark groups between 2009 and 2017 and peripartum controls.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Clinical information was collected on hemoglobin levels, platelet counts, and coagulation- and fibrinolysis-related variables. Fibrinolytic parameters were also measured and compared among the three groups before blood transfusion. Fibrinogen levels in all patients in the Clark group and most in the Non-Clark group decreased earlier than hemoglobin levels, which was consistent with the high hemoglobin/fibrinogen ratio and, thus, is a promising clinical marker for the earlier assessment of amniotic fluid embolism-related consumptive coagulopathy.
CONCLUSIONS: Earlier evaluations of consumptive coagulopathy and hyperfibrinolysis using the hemoglobin/fibrinogen ratio following preemptive treatment may reduce the occurrence or prevent the aggravation of severe coagulopathy in amniotic fluid embolism patients.
参考来源
- Oda T, Tamura N, Ide R, et al. Consumptive Coagulopathy Involving Amniotic Fluid Embolism: The Importance of Earlier Assessments for Interventions in Critical Care. Crit Care Med. 2020. PMID: 33031152. doi:10.1097/CCM.0000000000004665
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。